The ACR/CHEST ILD Guidelines in Practice: Register Now for This Informative Webinar

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

2016 Deadline Imposed by Meaningful Use Program Requires Immediate Attention: Sign Up for 2 Registries by Feb. 29 or Expect Financial Penalty

  |  

Meaningful Use may be changing but it is not going away—yet. Rheumatologists must sign up with two of three registries by Feb. 29 or pay significant financial penalties for not complying with this specific part of the Meaningful Use requirements. The three choices for registries include the Immunization Registry, the Syndromic Surveillance Registry and a…

Aetna’s Deal for Humana May Push Up Costs for Seniors

Diane Bartz  |  

WASHINGTON (Reuters)—Aetna Inc.’s plan to buy smaller insurer Humana Inc. for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP). Aetna’s proposed deal for Humana would combine Aetna’s 7% of the Medicare Advantage market with Humana’s 19%, and make…

U.S. Government Suspends Enrollment in Cigna Medicare Advantage, Drug Plans

Caroline Humer  |  

(Reuters)—The U.S. government has suspended new enrollment in Cigna Corp’s Medicare Advantage health plans for seniors and standalone Medicare prescription drug plans, citing noncompliance in its appeals and grievances procedures. The government said Cigna had deficiencies in its appeals and grievances processes in both Medicare Advantage and the Medicare prescription drug program, according to a…

Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

Laura Newman  |  

NEW YORK (Reuters Health)—Women with rheumatoid arthritis (RA) are at increased risk for cervical intraepithelial neoplasia (CIN), and those taking a tumor necrosis factor (TNF) inhibitor are at increased risk of cervical cancer, according to a study from Sweden. “Whether this (the increase in invasive cancers) was due to the TNF inhibitors, disease severity, or…

Opioid Investigated to Treat Acute & Chronic OA Pain; Plus New RA Treatment & More

  |  

In Phase 2 trials, the oral opioid, CR845, has proved promising in treating pain in patients with hip and knee osteoarthritis. Olokizumab is being investigated to treat RA, and in Canada, adalimumab has been approved to treat polyarticular JIA in 2–4 year-olds…

French ‘Cannabis’ Drug Trial Volunteer Dies

Reuters Staff  |  

RENNES, France (Reuters)—A man left brain dead after a drug trial in northwest France died on Sunday, said the hospital where he was being treated. The Rennes hospital said in a statement that five other volunteers were in stable condition after they were admitted last week. In total, 90 people took part in the trial of the drug made…

FDA Approves New Drugs for Pain

  |  

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

  |  

SAN FRANCISCO—“Interstitial lung disease is the last bastion of great medicine,” according to Paul Noble, MD, chair, Department of Medicine, director, Women’s Guild Lung Institute, Vera and Paul Guerin Distinguished Chair in Pulmonary Medicine, Cedars-Sinai Medical Center, Los Angeles. Making it great medicine, he said, are the many things still unknown about this disease. In…

Search for Infectious Triggers of Rheumatic Disease Could Yield Options to Block Process

  |  

SAN FRANCISCO—Two hundred years ago, physicians knew nothing about what caused various forms of arthritis. Today, we have more clues about what may trigger rheumatic diseases, but still can’t pinpoint the culprits that set scores of inflammatory conditions in motion. Researchers discussed some of the background and recent findings that point to what immunologists call…